{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-23-000064","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.983254+00:00","generated_at":"2026-06-10T09:11:50.747489+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Selecta Biosciences approves retention bonuses for five executives","bullets":["Carsten Brunn (CEO) and Blaine Davis each receive 2x annual salary bonus; Peter Traber 1.5x; Takashi Kei Kishimoto 1x; Lloyd Johnston 2x.","Bonus payable on first payroll after March 31, 2024 if executive remains employed in good standing.","Compensation Committee may accelerate payment or waive service requirements at its discretion.","Retention bonuses aim to incentivize key leadership continuity through March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-23-000064","json":"https://secwatch.observer/filing/0001453687-23-000064.json","markdown":"https://secwatch.observer/filing/0001453687-23-000064.md","text":"https://secwatch.observer/filing/0001453687-23-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000064/0001453687-23-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368723000064/selb-20230825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:11:50.747489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}